ClinicalTrials.gg
CompletedNCT02182193Updated Jul 18, 2014

Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers

A Phase 1 interventional study of BIBF 1120 capsules charge 1 and BIBF 1120 capsules charge 2 in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 21 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
21 Years to 55 Years
Sex
Male
01

Study summary

To assess pharmacokinetics and the relative bioavailability of a single dose of BIBF 1120 soft gelatine capsule charge 1 vs. BIBF 1120 soft gelatine capsule charge 2 vs BIBF 1120 drinking solution in healthy male subjects respectively. To establish an in-vitro-in-vivo correlation (IVIVC) for oral soft gelatine capsules with 150 mg BIBF 1120 in healthy male volunteers (if feasible)

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects as determined by results of screening
  2. Signed written in accordance with GCP and local legislation
  3. Age ≥21 and ≤55 years
  4. ≥18.5 kg/m2 and ≤29.9 kg/m2

Exclusion criteria

Exclusion Criteria:

  1. Any finding of the medical examination (including blood pressure, pulse rate and ) deviating from normal and of clinical relevance
  2. History or current gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders
  3. History of relevant orthostatic hypotension, fainting spells and blackouts
  4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  5. Chronic or relevant acute infections
  6. History of allergy/ (including drug allergy or its ) which is deemed relevant to the trial as judged by the investigator
  7. History of any bleeding disorder including prolonged or habitual bleeding, other hematologic disease or cerebral bleeding (e.g. after a car accident) or commotio cerebri
  8. Intake of drugs with a long half-life (> 24 hours) within 1 month prior to administration
  9. Use of any drugs which might influence the results of the trial within 14 days prior to administration or during the trial
  10. Participation in another trial with an drug within 2 months prior to administration or during trial
  11. Smoker (> 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from smoking on study days
  12. Alcohol abuse (> 60 g/day)
  13. Drug abuse
  14. Blood donation (more than 150 mL within 4 weeks prior to administration or during the trial)
  15. Excessive physical activities within 5 days prior to administration or during the trial
  16. Any laboratory value outside the reference range that is of clinical relevance
  17. Female gender
  18. Male subjects refuse to minimize the risk of female partners becoming pregnant from the first dosing day until 3 months after the completion of the study. Acceptable methods of for male volunteers include a vasectomy no less than 3 months prior to dosing, barrier contraception or a medically accepted contraceptive method. For female partners of male volunteers, acceptable methods of contraception include intra-uterine device, tubal ligation, hormonal contraceptive since at least two months and diaphragm with spermicide
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    BIBF 1120 capsules charge 1

    Drug: BIBF 1120 capsules charge 1

  • Experimental
    BIBF 1120 capsules charge 2

    Drug: BIBF 1120 capsules charge 2

  • Active comparator
    BIBF 1120 drinking solution

    Drug: BIBF 1120 drinking solution

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve of the analyte from zero time (pre-dose) extrapolated to infinity (AUC0-∞)

    Time frame: 1 h pre dose and up to 48 h after drug administration

  2. Individual maximum observed concentrations of the analyte in plasma (Cmax)

    Time frame: 1 h pre dose and up to 48 h after drug administration

Secondary outcomes

  1. Area under the plasma concentration-time curve of the analyte over the time interval from time zero (pre-dose) to 24 hours (AUC0-24)

    Time frame: 1 h pre dose and up to 24 h after drug administration

  2. time from dosing to the maximum concentration of the analyte in plasma (tmax)

    Time frame: 1 h pre dose and up to 48 h after drug administration

  3. Terminal rate constant in plasma (λz)

    Time frame: 1 h pre dose and up to 48 h after drug administration

  4. Terminal half-life of the analyte in plasma (t1/2)

    Time frame: 1 h pre dose and up to 48 h after drug administration

  5. Mean residence time of the analyte in the body after oral administration (MRTpo)

    Time frame: 1 h pre dose and up to 48 h after drug administration

  6. Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)

    Time frame: 1 h pre dose and up to 48 h after drug administration

  7. Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)

    Time frame: 1 h pre dose and up to 48 h after drug administration

  8. Change in vital signs (blood pressure, pulse rate)

    Time frame: Baseline, up to 24 hours after drug administration

  9. Change in routine laboratory values

    Time frame: pre-dose, up to 48 hours after drug administration

  10. Change in ECG

    Time frame: pre-dose, 4 hours after drug administration, day 32

  11. Occurrence of adverse events

    Time frame: up to 32 days after drug administration

  12. Assessment of tolerability by investigator on a 4 point scale

    Time frame: 48 hours after drug administration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006 and a primary completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2014
First posted
Jul 8, 2014
Start
Sep 2006
Primary completionActual
Nov 2006
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02182193
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Sep 2006
Primary completion
Nov 2006
Last update
Jul 18, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion